匯豐推出7億美元「大灣區+」醫療信貸基金 加碼支持大灣區新經濟發展
匯豐宣布推出7億美元的信貸基金計劃,為大灣區內高速成長的醫療產業企業提供信貸融資。該專項信貸基金為醫療產業而設,涵蓋的企業範疇包括醫療科技、醫療服務、製藥、醫療器械、研發及生產外判服務,以及第三方醫療機構等。
匯豐表示,計劃旨在支持已具可行業務模式及營運現金流,並處於盈利前期的企業,提供優先債務融資以配合其業務發展。
匯豐自2019年6月起透過「大灣區+」科技信貸基金為超過50家新一代成長期企業提供信貸融資,有見客戶對該科技信貸基金的需求上升,已增加計劃的信貸額度,由原來的8.8億美元增至11.3億美元。連同新推的「大灣區+」醫療信貸基金,匯豐已先後為大灣區新經濟領域下的公司預留超過18億美元的信貸額度。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.